sodium nitroprusside Iontophoresis

PreclinicalSmall molecule

sodium nitroprusside Iontophoresis is one of 9 small molecule programs targeting Leprosy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeprosyActive, not recruiting

LeprosyPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Leprosy

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Approved

1 2

Lamprene

Neoral

Avlosulfon

1 5

Glucophage

EMD Serono

Phase 2

1 6

BE-PEP Rifampicin

IInstitute of Tropical Medicine, Belgium

Phase 3

2 7

sodium nitroprusside Iontophoresis

CCurt Treu

Preclinical

1 8

Acetylcholine Iontophoresis

JJames J. Peters Veterans Affairs Medical Center

Preclinical

1 9

Clofazamine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leprosy1 trial

Microcirculatory Impairment in Patients With Leprosy

Completed·CCurt Treu·N/A·NCT02085317·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for sodium nitroprusside Iontophoresis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sodium nitroprusside Iontophoresis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sodium nitroprusside Iontophoresis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Curt Treu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCurt Treu

sodium nitroprusside Iontophoresis

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leprosy1 trial

References

Drug Info

Quick Facts

Related News